Ann: European approvals and milestone payments for Lenzetto, page-27

  1. 42 Posts.
    The stock has bottomed out, with the European approvals and payments I think its uphill for the SP.

    The macros are there, the shorts have dropped and the company is profitable which I need to stress is rare for pharmaceuticals who burn through cash to become profitable.

    The company has actual value and with contracts with giants like Eli Lilly, its just a long hold. Any short term traders are probably best to overlook the stock.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.6¢
Change
-0.002(11.1%)
Mkt cap ! $6.548M
Open High Low Value Volume
2.0¢ 2.0¢ 1.6¢ $39.34K 2.216M

Buyers (Bids)

No. Vol. Price($)
8 971151 1.6¢
 

Sellers (Offers)

Price($) Vol. No.
1.7¢ 565000 1
View Market Depth
Last trade - 16.10pm 31/07/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.